Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;12(2):e220016.
doi: 10.2217/cer-2022-0016. Epub 2023 Jan 9.

A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer

Himani Aggarwal  1 , Kerigo Ndirangu  2 , Katherine B Winfree  1 , Catherine Elizabeth Muehlenbein  1 , Emily Zhu  1 , Vanita Tongbram  2 , Howard Thom  3
Affiliations
Review

A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer

Himani Aggarwal et al. J Comp Eff Res. 2023 Feb.

Abstract

Introduction: In the absence of head-to-head trials comparing immunotherapies for advanced nonsquamous non-small-cell lung cancer (NsqNSCLC), a network meta-analysis (NMA) was conducted to compare the relative efficacy of these treatments. Materials & methods: A systematic literature review of randomized controlled trials evaluating first-line-to-progression and second-line treatments for advanced NsqNSCLC informed Bayesian NMAs for overall survival (OS) and progression-free survival (PFS) end points. Results: Among first-line-to-progression treatments, pembrolizumab + pemetrexed + platinum showed the greatest OS benefit versus other regimens and a PFS benefit versus all but three regimens. Among second-line treatments, an OS benefit was seen for atezolizumab, nivolumab and pembrolizumab versus docetaxel. Conclusion: Pembrolizumab + pemetrexed + platinum showed the maximum OS benefit in the first-line setting. In the second-line setting, anti-PD-1/anti-PD-L1 monotherapies were better than docetaxel.

Keywords: immunotherapy; network meta-analysis; nonsquamous NSCLC; pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Figures

Figure 1.
Figure 1.. Preferred Reporting Items of Systematic reviews and Meta-Analyses publication screening and selection.
NMA: network meta-analysis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. WHO. Cancer Fact Sheet. Secondary Cancer Fact Sheet (2018). www.who.int/news-room/fact-sheets/detail/cancer
    1. Planchard D, Popat S, Kerr K et al. ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl. 4), iv192–iv237 (2018). - PubMed
    1. Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS. Immunotherapy in lung cancer. Transl. Lung Cancer Res. 3(1), 53–63 (2014). - PMC - PubMed
    1. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027), 1540–1550 (2016). - PubMed
    1. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015). - PMC - PubMed

MeSH terms